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Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell malignancy caused
by human T-cell lymphotropic virus 1. Treatment options for acute ATL patients
include chemotherapy, stem cell transplantation, and recently the anti-chemokine
(C-C motif) receptor 4 antibody, although most patients still have a poor progno-
sis and there is a clear need for additional options. HBI-8000 is a novel oral his-
tone deacetylase inhibitor with proven efficacy for treatment of T-cell
lymphomas that recently received approval in China. In the present study, we
evaluated the effects of HBI-8000 on ATL-derived cell lines and primary cells
obtained from Japanese ATL patients. In most cases HBI-8000 induced apoptosis
in both primary ATL cells and cell lines. In addition, findings obtained with DNA
microarray suggested Bim activation and, interestingly, the contribution of the
NLR family, pyrin domain containing 3 (NLRP3) inflammasome pathway in HBI-
8000-induced ATL cell death. Further investigations using siRNAs confirmed that
Bim contributes to HBI-8000-induced apoptosis. Our results provide a rationale
for a clinical investigation of the efficacy of HBI-8000 in patients with ATL.
Although the role of NLRP3 inflammasome activation in ATL cell death remains
to be verified, HBI-8000 may be part of a novel therapeutic strategy for cancer
based on the NLRP3 pathway.
A dult T-cell leukemia/lymphoma (ATL) is an aggressivemalignancy of mature T-lymphocytes that result from
infection with human T-cell lymphotropic virus 1 (HTLV-1).
The disease can be divided into four stages: indolent, chronic,
lymphoma, and acute, with no accepted curative therapy pre-
sently available.(1–3) Outside of clinical trials, the predominant
treatment option for acute, lymphoma, and unfavorable chronic
type is sequential chemotherapy, whereas additional options
for aggressive disease include azidothymidine and interferon-a
and allogenic hematopoietic stem cell transplantation.(2,3)
Development of additional therapies has been slow, with the
anti-chemokine (C-C motif) receptor 4 (CCR4) antibody moga-
mulizumab the only novel agent introduced in recent years.
Although approximately 90% of ATL patients with aggressive
disease express CCR4,(4,5) not all patients eligible to receive
mogamulizumab respond to treatment; those who do often
show relapse or become refractory soon thereafter.(6) Thus, the
prognosis for most affected patients remains poor and there is
a clear unmet need for novel therapeutic options.
Histone deacetylases (HDACs) are epigenetic modulators
that regulate key cellular processes, including proliferation
and survival, by modulating gene expression and protein
activity. Histone deacetylase inhibitors (HDACi) induce re-
expression of genes repressed during oncogenesis, including
those involved in growth arrest, DNA damage repair, and
apoptosis. As a consequence, HDACi have been shown to
be potent inducers of growth inhibition and apoptosis in a
variety of transformed cells, including those related to lym-
phoid malignancies.(7,8) At present, four different HDACi
have been approved for treatment of T-cell lymphoma,
including romidepsin and belinostat for peripheral T-cell
lymphoma (PTCL), vorinostat and romidepsin for cutaneous
T-cell lymphoma, and more recently the orally administered
HBI-8000 (chidamide) for PTCL was approved in China.
Even though there are similarities between PTCL, cutaneous
T-cell lymphoma, and ATL, and while previously published
data indicate that HDACi cause apoptosis of ATL cells and
HTLV-1-transformed cell lines,(9,10) none of the approved
HDACi have been studied in regard to clinical efficacy for
ATL.
HBI-8000 is an orally bioavailable new chemical entity from
the benzamide class of HDACi rationally designed to specifi-
cally block the catalytic pocket of class I HDACs.(11,12) HBI-
8000 has shown direct antitumor activity and is also known to
enhance immune cell-mediated tumor cytotoxicity by both nat-
ural killer cells and tumor-specific CTLs.(12–17) In addition, its
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efficacy as monotherapy for T-cell lymphomas has been
proven.(18)
In the present study, we evaluated the effects of HBI-8000
in ATL-derived cell lines and fresh primary ATL cells
obtained from ATL patients. Our results indicate that HBI-
8000 inhibits cell viability in both primary ATL cells and
ATL-derived cell lines. The results provide evidence to sup-
port further investigation of the potential utility of HBI-8000
for ATL patients.
Materials and Methods
Sample preparation and cell cultures. Eleven samples were
taken from 10 patients diagnosed with aggressive type ATL,
based on Shimoyama’s diagnostic criteria (Table S1).(1) The
diagnosis of ATL was confirmed by monoclonal integration of
HTLV-1 proviral DNA (Southern blotting; data not shown) in
all cases.(19) Peripheral blood mononuclear cells were obtained
from ATL patients and healthy adult volunteers by density gra-
dient centrifugation using a Lympho-prep (Axis Shield, Oslo,
Norway). CD4+ lymphocytes from healthy donors were puri-
fied from PBMCs by the magnetic bead method (CD4+ T Cell
Isolation Kit; Miltenyi Biotec, Auburn, CA, USA). The
PBMCs from ATL patients contained more than 85% leukemic
cells and were maintained in medium supplemented with
10 ng/mL interleukin-2 (IL2). Among 10 patients with ATL,
ATL cases 5, 7, 9, and 10 had cells of sufficient quantity to
carry out Western blotting or protein expression array. Follow-
ing approval by the Ethics Committee of Nagasaki University
Hospital (No. 13102878; Nagasaki, Japan), all patient samples
were obtained after receiving informed consent.
Cell lines and cell cultures. The ATL-derived lines KOB,
KK1, ST1, SO4, LMY1, and LMY2 were established from
patients with aggressive type ATL and kept in our labora-
tory.(20,21) LMWT5 is a newly established cell line from
PBMCs from a patient with acute type ATL. The primary
ATL origin of the cells was confirmed by concordance of the
results of Southern blotting (data not shown). Human T-cell
leukemia cell line Jurkat and human monocytic leukemia cell
line THP-1 were obtained from ATCC (Manassas, VA, USA).
ST1, Jurkat, and THP-1 cells were maintained in medium
(RPMI-1640 supplemented with 10% FBS) in an IL2-indepen-
dent manner. Other cell lines were maintained in medium sup-
plemented with 10 ng/mL IL2. In a previous study, we
clarified that KOB, LMY1, LMY2, and ST1 cells have wild-
type p53.(22)
Chemicals and assays of cell viability, apoptosis, and cell cycle.
HBI-8000 (HUYA Bioscience International, San Diego, CA,
USA) was used in this study. The MTS cell viability assay
was carried out using a Cell Titer 96 Aqueous Cell Prolifera-
tion Assay kit (Promega, Madison, WI, USA). Cells were pre-
pared for cell cycle evaluation using a Cell Cycle Test kit (BD
Biosciences, San Jose, CA, USA). Apoptosis induction was
determined by annexin V/propidium iodide (PI) (Bender
Medsystems, Vienna, Austria), mitochondrial outer membrane
permeability using a Mitochondrial Membrane Potential
(MMP) Assay Kit (Cayman Chemical, Ann Arbor, MI, USA),
and caspase-3 activation with a fluorometric assay (MBL,
Woburn, MA, USA). A cell cycle test, annexin V/PI assay,
MMP Assay, and caspase-3 assay were carried out by Flow-
Cytometry (FCM) using a FACS Diva software (BD Bio-
sciences).
DNA microarray analysis. Total RNA was extracted using a
PureLink RNA micro kit (Life Technologies, Carlsbad, CA,
USA). RNA integrity was assessed using a 2100 Bioanalyzer
(Agilent, Palo Alto, CA, USA). Double-stranded cDNA and
biotinylated cRNA were synthesized using a BioArray RNA
labeling kit (Enzo, Farmingdale, NY, USA). Labeled RNA
was then fragmented and hybridized to SurePrint G3 Human
Gene Expression 8x60K version 2.0 (Agilent). The arrays were
scanned using The SureScan Microarray Scanner G2600D
(Agilent) and analyzed with Agilent Feature Extraction Soft-
ware Version 11.5.1.1(Agilent).
Mutation analysis of p53. Reverse transcription–PCR was
carried out to amplify the sequence targeting the ORF of p53
(GenBank Accession number NM_000546) as described previ-
ously.(22)
Quantitative real-time RT-PCR. The mRNA levels for Bim,
nucleotide-binding domain and leucine-rich repeat containing
gene (NLR) family, pyrin domain containing 3 (NLRP3),
p21WAF1/CIP1, and porphobilinogen deaminase were measured
using a LightCycler480 PCR System (Roche Diagnostics,
Basel, Switzerland) as described previously.(23) Primers and
probes used in this study were summarized in Table S2. To
normalize the results for variability in concentration and integ-
rity of RNA and cDNA, the PBGD gene was used as an inter-
nal control for each sample.
PathScan stress and apoptosis signaling antibody array analy-
sis. The PathScan Stress and Apoptosis Signaling Antibody
Array Kit (Cell Signaling Technology, Beverly, MA, USA)
allows for simultaneous detection of 19 different signaling
molecules. Whole-cell lysates were prepared and incubated on
the slides overnight, followed by a biotinylated detection anti-
body cocktail. Streptavidin-conjugated HRP and LumiGLO
Reagent, containing in the kit, were then used to visualize by
chemiluminescence. Slide images were captured with an image
analyzer LAS3000 (Fujifilm, Tokyo, Japan) and spot signals
were quantified (Multigauge version 3.0; Fujifilm).
Western blotting and antibodies. Western blot analysis was
carried out as previously described.(24) Analyses were under-
taken using antibodies to p53 (DO-1), acetylated histone-H3
and -H4 (Merck, Darmstadt, Germany), caspase-1, cleaved cas-
pase-1, Bim, BAX, Bcl-2, Bcl-xL, p21, IKBa, Ij B kinase
(IKK)a, IKKb, IKKc, and NLRP3 (Cell Signaling Technol-
ogy), and b-actin (Sigma, St. Louis, MO, USA).
Transfection and siRNA experiments. Transfection was per-
formed with a Neon Transfection System MPK5000S (Invitro-
gen, Carlsbad, CA, USA). The transfection programs for KOB
and LMY1 (No. 24) were run in such a manner that cell viability
and transfection efficiency would be compatible (data not
shown). Twelve hours after transfection, cells were treated with
or without HBI-8000 and processed for experiments. Two differ-
ent siRNAs were prepared against each target as follows: Bim,
Silencer Select Validated siRNA s195011 (#1) and Silencer
Select siRNA s195012 (#2); NLRP3, Silencer Select siRNA
s41555 (#1), s41556 (#2). As a control siRNA, Silencer negative
control #1 (Applied Biosystems, Foster City, CA) was used.
Statistical analysis. Student’s t-test with Welch’s correction
was used to calculate statistical significance. **P-values < 0.01
and *P-values < 0.05 were regarded as significant.
Results
HBI-8000 inhibits cell viability in ATL-derived cell lines. To
investigate the activity of HBI-8000 in ATL cells, two model
systems were used, both based on cells derived from ATL
patients. First, the activity of HBI-8000 was evaluated using
seven ATL cell lines and the non-ATL T-cell line Jurkat,
Cancer Sci | August 2016 | vol. 107 | no. 8 | 1125 © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Original Article
www.wileyonlinelibrary.com/journal/cas Hasegawa et al.
which is known as a good responder against HDACi.(8) All
cell lines tested showed decreased cell viability after 72 h of
HBI-8000 treatment (Fig. 1a). ST1 was relatively unresponsive
and showed only modest inhibition. The IC50 values of ATL
cells showing a response ranged from 0.7 to 1.7 lM (mean,
1.16 lM). These results indicated that sensitivities of ATL cell
lines to HBI-8000 are not inferior compared to Jurkat cells.
HTLV-1 infection, IL2-dependence, or p53 status did not have
an effect on the response to HBI-8000.
Apoptosis induction by HBI-8000 in ATL cells associated with
annexin-V binding, loss of mitochondrial membrane potential,
and caspase-3 activation. Apoptosis induction was measured
using four commonly used assays: annexin-V binding
(Fig. 1b), accumulation of cells in the sub-G1 cell cycle analy-
sis peak (Fig. 1c), the loss of MMP (Fig. 1d), and activation
of caspase-3 (Fig. 1e). The data obtained from the four differ-
ent methods used to detect cell death were consistent, and
revealed that a significant level of apoptosis was induced in
the KOB, LMY1, LMY2, LMWT5, and Jurkat lines, whereas
the KK1, SO4, and ST1 lines showed only modest apoptosis.
Consistent with previous findings,(25) HBI-8000 also induced
G1 cell cycle arrest in KK1, SO4, and ST1 cells (Fig. 1c).
HBI-8000 induces apoptosis in primary ATL cells. The effect of
HBI-8000 was also assessed using cells freshly obtained from
ATL patients (Table S1). The cells were treated with various
concentrations of HBI-8000 for 72 h, after which cell viability
was evaluated using an MTS assay. For the first screening
step, we treated seven ATL samples with 1.25–100 lM HBI-
8000 (Table S1). For more detailed observations, we used
20 lM as the maximum dose and carried out MTS assays with
six ATL samples, which included four new ATL samples, as
well as samples 1 and 7 from the screening experiment
(Fig. 2a, Table S1). Primary ATL cells, including two relapsed
cases and two unfavorable chronic type cases, responded to
HBI-8000 in a dose-dependent manner (mean IC50, 4.35 lM).
HBI-8000 showed cytotoxicity toward normal CD4 lympho-
cytes to some extent, whereas the ATL samples showed inhib-
ited cell viability at significantly lower concentrations
(Fig. S1). Importantly, ATL1 and ATL10, derived from
patients who relapsed after both combination chemotherapy
and mogamulizumab therapy, showed sensitivity to HBI-8000
that was similar to other primary ATL cells. Thus, our results
suggest that HBI-8000 may have activity in patients who have
developed resistance to standard therapeutic methods. Finally,
we investigated the cell death pattern using an annexin-V/PI
assay with ATL samples (Fig. 2b). The ATL samples tested
consisted of more than 50% annexin-V-positive cells, indicat-
ing that HBI-8000 induced apoptotic cell death in primary
ATL cells. In contrast, that of normal CD4 lymphocytes
showed <30%.
HBI-8000 caused acetylation of histones and activated tumor
suppressor genes in ATL cells. It is well established that hyper-
acetylation of histones following HDAC inhibition can
increase the gene expression of various tumor suppressors,
such as p53 and p21. We confirmed that HBI-8000 was effec-
tive for increasing the acetylation of histones H3/H4 in ATL
cell lines and primary ATL cells (Fig. 3a,b), and then sought
to determine the effect of HBI-8000 on protein expressions of
p53 and p21 by Western blot analysis. Previous results sug-
gested that p53 status does not determine the response to HBI-
8000; however, cells with wild-type p53 (KOB, LMY1)
showed increased expression of p53 and p21. KK1 cells with
mutated p53 showed accumulated p53 proteins and were not
changed by HBI-8000 treatment, but they nevertheless showed
increased p21 expression (Fig. 3c). In primary ATL cells,
ATL9 and 10 have wild-type p53 (Table S1) and showed acti-
vation of p53. Reminiscent of the cell line KK1, ATL7 may
possess mutant p53 in that it too showed accumulated p53 pro-
teins. Surprisingly, none of the primary ATL samples showed
increased p21 expression following HBI-8000 treatment
(Fig. 3d), yet they do not require p21 activation for HBI-8000-
induced apoptosis.(25) Only three cases (ATL1, 5, and 8), but
we further investigated the expression of p21 mRNA after
HBI-8000 treatment. These cases have mutant p53, however,
ATL1 showed upregulation of p21 mRNA. Thus, some ATL
cells may have the ability to upregulate p21 mRNA or protein
by HBI-8000 but did not correlate with sensitivities to HBI-
8000. Our results also suggested that ATL cells with wild-type
p53 may be able to reactivate p53 with the addition of HBI-
8000. Interestingly, normal CD4 lymphocytes are harmed to
some extent (Fig. S1) and the histones were acetylated
(Fig. 3b) but their tumor suppressor genes were not activated
by HBI-8000 (Fig. 3d).
DNA microarray and antibody array analysis. To address the
vital mechanisms of HBI-8000-induced ATL cell death, we
used DNA microarray and protein expression array analyses.
For the DNA microarray analysis, we used KOB and LMY1,
which showed apoptotic changes with HBI-8000 treatment,
and compared gene expression profiles between treated and
untreated cells. Genes with known functions related to apopto-
sis, cell cycle, cell death, or cell growth are arranged in order
of change in the expression (log2 ratio) in either direction
(Table 1). Among commonly observed changes, the upregula-
tion of Chemokine (C-C Motif) Ligands (CCL2 and CCL4)
Interleukin (IL) 9, IL13, and as well as molecules related to
cell-growth signaling such as the JAK/signal transducer and
activator of transcription pathway (IL9, IL13, and signal trans-
ducer and activator of transcription 4), and inflammasome-
related molecules (IL1b, tumor necrosis factor, c-interferon,
and NLRP3) were notable. In contrast, apoptosis facilitating
molecules such as FAS (CD95) and breast cancer 1, early
onset were downregulated. These results seem to be in contra-
diction to the observed HBI-8000-induced ATL cell death. A
possible explanation is that small numbers of apoptosis facili-
tators are activated by HBI-8000 that can overcome anti-apop-
totic or cell-growth signals. Considering that KOB and LMY1
Fig. 1. Apoptosis in adult T-cell leukemia/lymphoma (ATL)-derived cell lines induced by HBI-8000. (a) ATL-derived cell lines and Jurkat cells (2–
5 9 105/mL) were treated with either the vehicle or indicated concentrations of HBI-8000 for 72 h, then cell viability was evaluated using MTS
assay. All experiments were carried out in triplicate and the results are expressed as the mean  SD. (b–d) ATL-derived cell lines and Jurkat cells
(2–5 9 105/mL) were treated with either the vehicle or 4 lM HBI-8000 for 48 h, and collected. (b) Annexin-V/propidium iodide staining was car-
ried out and the percentage of annexin-V-positive cells was evaluated. Experiments were carried out in triplicate and the results are expressed as
the mean  SD. (c) Cell cycle analysis. The percentage of cells in the sub-G1, G1, S, and G2/M phase was evaluated. Increased numbers of cells in
the G1 phase and those with G1 arrest were observed among KK1 and SO4 cells treated with HBI-8000. (d) Evaluation of loss of mitochondrial
membrane potential. Cells were incubated with JC-1 dye and analyzed using FCM to determine the percentage with low JC-1 red fluorescence.
Except for KK1 cells, most of the cell lines showed decreased mitochondrial membrane potential (DwM). (e) Activated (cleaved) caspase-3 was
evaluated using an Apopcyto caspase-3 colorimetric assay kit. Values for fold induction of signaling (HBI-8000-treated cells/non-treated cells) are
indicated.
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undergo apoptosis by way of the intrinsic pathway (Fig. 1d),
upregulation of BCL2L11 (Bim) is consistent with the obser-
vation.
The findings from the protein expression array assays
showed that cleavage of caspase-3 and -7, and poly(ADP-
ribose) polymerase(26) are common phenomena in cell lines
and primary ATL samples (Table S3). These results support
previous findings showing apoptosis induced by HBI-8000 in
ATL cells. Among other molecules, an apparent upregulation
of IjBa was a common phenomenon in ATL cells except
KK1.(27) Western blotting revealed that there were tendencies
for increased expression of IkBa and decreased expression of
IKKs in both the cell lines and primary ATL cells (Fig. S2).
These results indicate that HBI-8000 contributes to ATL cell
death partly through nuclear factor-jB inhibition.
Analysis of intrinsic apoptotic pathway focusing on activation
of Bim. Bim is a pro-apoptotic protein that induces apoptosis
by binding to and antagonizing anti-apoptotic members of the
Bcl-2 family.(28) To investigate the behavior of Bim, we under-
took quantitative PCR for Bim and Western blot analysis for
key molecules interacting with Bim (Fig. 4). Quantitative PCR
confirmed upregulation of Bim by HBI-8000 at the mRNA
level. Importantly, this upregulation was commonly observed
in KOB and LMY1 cells, as well as the other cells, but not in
normal CD4 lymphocytes. In accordance with the PCR results,
the protein expression of Bim was remarkably upregulated in
KOB, LMY1, and all of the three primary ATL cells exam-
ined. Downregulation of Bcl-2 and Bcl-xL was apparent,
whereas Bax showed no change in the KOB and LMY1 cell
lines. Among the primary ATL cells, ATL9 and 10 showed
(a) (b)
Fig. 2. HBI-8000 inhibits cell viability and induces apoptosis in primary adult T-cell leukemia/lymphoma (ATL) cells. Cells (1 9 106/mL) were trea-
ted with either vehicle or indicated concentrations of HBI-8000. (a) After 72 h, cell viability was evaluated using MTS assay. All experiments were
carried out in triplicate and the results are expressed as the mean  SD. (b) After 48 h, annexin-V/propidium iodide staining was carried out and




Fig. 3. Analysis of acetylated histones, tumor
suppressor genes, and antibody array in adult T-cell
leukemia/lymphoma (ATL) cell lines and primary
ATL cells. (a–d) ATL cell lines (2–5 9 105/mL),
primary ATL cells, and normal CD4 lymphocytes
(1 9 106/mL) were treated with either the vehicle
or the indicated concentrations of HBI-8000 for
48 h, then collected. Whole-cell lysates were
prepared and Western blotting was carried out. In
the membrane for CD4 lymphocytes, KOB cells
treated with HBI-8000 were used as positive
control.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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downregulation of Bcl-xL, and ATL7 and 10 showed moderate
upregulation of Bax. These results support the previously noted
speculation that small numbers of apoptosis facilitators are
activated by HBI-8000, which are able to overcome anti-apop-
totic or cell-growth signals. Western blotting for normal CD4
lymphocytes was undertaken to compare with that of ATL
samples and they did not alter expressions of Bax, Bim, Bcl-2,
or Bcl-xL by HBI-8000 (Fig. 4d).
Analysis of activation of NLRP3 inflammasome signals. The
inflammasome pathway is responsible for activation of inflam-
matory processes and induces cell pyroptosis, a process of pro-
grammed cell death distinct from apoptosis.(29) NLRP3 is an
inflammasome-forming nucleotide-binding oligomerization
domain-like receptor that activates procaspase-1, leading to
maturation of IL1b. Like other caspases, procaspase-1 is acti-
vated in a proteolytic manner (cleaved caspase-1).(30) As our
microarray analysis results strongly suggested the activation of
NLRP3 inflammasome-related molecules, we carried out fur-
ther quantitative PCR assays for NLRP3, and Western blotting
for NLRP3 and caspase-1 (Fig. 4b,e,f). In accordance with the
results of microarray analysis, quantitative PCR confirmed
upregulation of NLRP3 by HBI-8000 at the mRNA level in
the ATL cell lines and primary ATL cells examined. Mean-
while, the level of mRNA and protein in normal CD4 lympho-
cytes did not upregulate NLRP3 and caspase-1 in response to
HBI-8000. Western blot analysis showed that KOB cells did
Table 1. Microarray analysis of KOB and LMY1 adult T-cell leukemia/
lymphoma cells
Symbol Gene KOB LMY1
Upregulated genes
IL1B Homo sapiens interleukin 1, b (IL1B),
mRNA [NM_000576]
11.0 2.5
CCL4 Homo sapiens chemokine (C-C motif)
ligand 4 (CCL4), transcript variant 1,
mRNA [NM_002984]
7.8 3.7
IL9 Homo sapiens interleukin 9 (IL9) 7.5 6.0
SERPINB2 Homo sapiens serpin peptidase inhibitor,
clade B (ovalbumin), member 2
(SERPINB2)
7.3 4.6
CCL2 Homo sapiens chemokine (C-C motif)
ligand 2 (CCL2)
6.3 5.3
BCL2L11 Homo sapiens BCL2-like 11 (apoptosis
facilitator) (BCL2L11)
5.3 3.2
CTLA4 Homo sapiens cytotoxic T-lymphocyte-
associated protein 4 (CTLA4)
5.2 1.6
IL13 Homo sapiens interleukin 13 (IL13) 5.1 4.6
IL3RA Homo sapiens interleukin 3 receptor, a
(low affinity) (IL3RA)
4.8 2.5








NLRP3 Homo sapiens NLR family, pyrin domain
containing 3 (NLRP3)
4.4 2.4
IER3 Homo sapiens immediate early response 3
(IER3)
4.4 7.2
BCL2A1 Homo sapiens BCL2-related protein A1
(BCL2A1)
4.0 1.8
IFNG Homo sapiens interferon, gamma (IFNG) 3.9 2.8
TNF Homo sapiens tumor necrosis factor (TNF) 3.8 1.6
SNAI1 Homo sapiens snail homolog 1
(Drosophila) (SNAI1)
3.6 2.5
STAT4 Homo sapiens signal transducer and
activator of transcription 4 (STAT4)
3.5 2.2
DHRS2 Homo sapiens dehydrogenase/reductase
(SDR family) member 2 (DHRS2)
3.0 2.6
LGMN Homo sapiens legumain (LGMN) 2.7 4.6
IL24 Homo sapiens interleukin 24 (IL24) 2.5 6.1
Downregulated genes
IL4 Homo sapiens interleukin 4 (IL4) 3.7 1.2
FAS Homo sapiens Fas (TNF receptor
superfamily, member 6) (FAS)
3.0 1.3
TSC22D3 Homo sapiens TSC22 domain family,
member 3 (TSC22D3)
2.4 2.1
CHAC1 Homo sapiens ChaC, cation transport
regulator homolog 1 (E. coli) (CHAC1)
2.3 2.1
JMY Homo sapiens junction mediating and
regulatory protein, p53 cofactor (JMY)
2.3 1.4
SERPINH1 Homo sapiens serpin peptidase inhibitor,
clade H (HSP47), member 1, (SERPINH1)
2.2 1.2
HDAC9 Homo sapiens histone deacetylase 9
(HDAC9)
2.1 1.1
PPP1R15A Homo sapiens protein phosphatase 1,
regulatory subunit 15A (PPP1R15A)
2.1 1.1
Table 1 (Continued)
Symbol Gene KOB LMY1
RNF7 Homo sapiens ring finger protein 7
(RNF7)
2.0 1.9
HDAC7 Homo sapiens histone deacetylase 7
(HDAC7)
1.9 1.1
IRAK4 Homo sapiens interleukin-1 receptor-
associated kinase 4 (IRAK4)
1.9 1.1
INPP5D Homo sapiens inositol polyphosphate-5-
phosphatase, 145 kDa (INPP5D)
1.7 1.9
IL9R Homo sapiens interleukin 9 receptor
(IL9R)
1.6 1.7
ADA Homo sapiens adenosine deaminase
(ADA)
1.6 1.5
BNIP3 Homo sapiens BCL2/adenovirus E1B
19 kDa interacting protein 3 (BNIP3)
1.5 1.5
FHL2 Homo sapiens four and a half LIM
domains 2 (FHL2)
1.3 2.0
CENPH Homo sapiens centromere protein H
(CENPH)
1.2 1.5
RAD51 Homo sapiens RAD51 homolog (S.
cerevisiae) (RAD51)
1.2 1.7
BRCA1 Homo sapiens breast cancer 1, early onset
(BRCA1)
1.1 1.9
MUC1 Homo sapiens mucin 1, cell surface
associated (MUC1)
1.1 1.9
CCNG2 Homo sapiens cyclin G2 (CCNG2) 1.0 2.1
Cells (2–5 9 105/mL) were treated with either vehicle or 4 lM HBI-
8000 for 16 h, then DNA microarray analysis was carried out. Upregu-
lated genes and downregulated genes in KOB cells are arranged in
descending and ascending orders of fold change (log2 ratio), respec-
tively. Among them, we selected those with known functions related
to apoptosis, cell cycle, cell death, and cell proliferation.
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not express NLRP3 or procaspase-1a, but rather showed
decreased expression of procaspase-1 isoforms. In contrast,
LMY1 showed apparent upregulation of NLRP3 and procas-
pase-1a, while the expression of caspase-1 isoforms was
decreased. Among the primary ATL cells, ATL7 and 10
showed decreased expression of procaspase-1a and increased
expression of cleaved caspase-1, and ATL9 showed decreased
expression of procaspase-1 isoforms and increased expression
of cleaved caspase-1. Therefore, depending on the cell types,
there was a tendency for NLRP3 and caspase-1 to be activated
by HBI-8000.
Bim plays critical role in initiating HBI-8000-induced apopto-
sis. Cell viability assays revealed that targeting Bim
(siRNA#1 and #2) significantly repressed HBI-8000-induced
cell death in KOB and LMY1 cells (Fig. 5a). The proportion
of intact cells in the si-control group was 40–60%, whereas
that in the si-Bim group increased to approximately 80%
after treatment with HBI-8000. Similar inhibitory effects by
si-Bim were observed in annexin-V/PI assay findings
(Fig. 5b). Representative results of Western blotting using
siRNA#1 were shown on Figure 5(c). In cells where NLRP3
induction by HBI-8000 was detectable (LMY1), Western
blotting revealed that si-Bim suppressed the activation of
Bim, but not that of NLRP3. These results indicate that Bim
plays a critical role in initiating HBI-8000-induced apoptosis
in KOB and LMY1 cells.
Possible contribution of NLRP3 inflammasome in HBI-8000-
induced cell death. We also carried out siRNA experiments tar-
geting NLRP3. Cell viability assays revealed that siRNAs
against NLRP3 significantly repressed HBI-8000-induced cell
death in KOB and LMY1 cells (Fig. 5a). Similar inhibitory
effects by si-NLRP3 were observed in annexin-V/PI assay
findings (Fig. 5b). Significant inhibition of apoptosis was
observed in LMY1 cells by use of siRNAs against NLRP3 and
a similar tendency was seen in KOB cells, although it was not
statistically significant. Western blot analysis revealed that si-
NLRP3 suppressed the activation of NLRP3 but not that of
Bim in LMY1 cells (Fig. 5c). Together, these results suggest
that activation of NLRP3 is important for HBI-8000-induced
cell death of LMY1 cells.
(a) (b) (c)
(d) (e) (f)
Fig. 4. Analysis of intrinsic apoptotic and NLRP3 pathways in HBI-8000-induced cell death. (a, b) Adult T-cell leukemia/lymphoma (ATL) cell lines
(2–5 9 105/mL), primary ATL cells, and normal CD4 lymphocytes (1 9 106/mL) were treated with 4 or 20 lM HBI-8000 for 24 h, and collected.
Quantitative RT-PCR assays for Bim, NLRP3, and porphobilinogen deaminase were carried out. Values for fold induction (HBI-8000 treated/un-
treated cells) after calculation of the relative ratios as compared to porphobilinogen deaminase are indicated. Quantitative data for Bim in HBI-
8000-treated KK1 cells and NLRP3 in HBI-8000-treated SO4 cells showed increases. However, the levels in non-treated cells were lower than the
detectable limit (star). Similarly, quantitative data for Bim in non-treated LMWT5 cells, and NLRP3 in non-treated KOB and KK1 cells showed
quite low values. (c–f) Two ATL cell lines (2–5 9 105/mL), three types of primary ATL cells, and normal CD4 lymphocytes (1 9 106/mL) were trea-
ted for 48 and 24–48 h, respectively, with either the vehicle or the indicated concentrations of HBI-8000. After collecting cells, Western blot anal-
ysis was carried out. In the membrane for CD4 lymphocytes, KOB cells treated with HBI-8000 or THP-1 cells were used as positive control. The
antibody for procaspase-1 used in this study is known to detect caspase-1 isoforms (b, c, d) as well as caspase-1a. Casp, caspase.
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Fig. 5. Knockdown experiments using siRNA of
Bim and NLRP3 in HBI-8000-induced cell death. At
12 h after transfection, cells (1–2 9 105/mL) were
incubated for 24 h with either the vehicle or 1–
2 lM HBI-8000. (a) Cell viability relative to
untreated cells in each experiment was evaluated
using MTS assay. (b) The percentage of annexin-V-
positive cells was evaluated by FCM. Results in 5 (a,
b) are expressed as the mean  SD for three
independent experiments and were analyzed using
Student’s t-test with Welch’s correction (*P < 0.05,
**P < 0.01) as compared with HBI8000-treated si-
Control cells. (c) After transfection using si-Control,
siRNA#1, or #2, cells (1–2 9 105/mL) were incubated
for 24 h with either vehicle or 1–2 lM HBI-8000.
Cells were harvested and Western blot analysis was
carried out. Representative results using siRNA#1
are shown.
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Discussion
Accumulated evidence supports the notion that HDACi have
therapeutic value for ATL.(9,10,31) However, none of the
approved HDACi therapies have been studied in regard to clin-
ical efficacy for ATL. The China Food and Drug Administra-
tion recently granted approval for use of HBI-8000, the
world’s first orally available HDACi for treatment of relapsed
or refractory PTCL.(18) Consistent with its activity for PTCL,
HBI-8000 induced cell cycle arrest and apoptosis in ATL-
derived cell lines and, perhaps more importantly, induced
apoptosis of treatment-naive or relapsed patient-derived ATL
cells. A phase I study of HBI-8000 in non-Hodgkin’s lym-
phoma including ATL patients is underway in Japan, with
phase II studies for ATL/PTCL in the planning stage.
The pro-apoptotic molecule Bim has recently attracted
increasing attention as a target for tumor therapy, with ima-
tinib, gefitinib, bortezomib, and the Bim protein itself spot-
lighted as current and future Bim-targeting therapeutic
agents.(32,33) Bolden et al. investigated the ability of HDACi to
affect the growth and survival of tumor cells whilst leaving
normal cells relatively unharmed, and found that Bim is a key
molecule in vorinostat-induced apoptosis of cancer cells.(34) It
has been shown that HTLV-1 Tax has a pro-survival role in
infected T cells by enhancing expression of the Bcl-2 family
of anti-apoptotic proteins. Very recently, several reports
pointed out the importance of the role of Bim in HTLV-1
infected cells. M€uhleisen et al. reported that HTLV-1 Tax
downregulates Bim expression by enhancing hypoxia-inducible
factor-1a protein expression, while siRNA knockdown of the
hypoxia-inducible factor-1a increased the expression level of
Bim, and death receptor induced apoptosis in HTLV-1-infected
leukemic T-cell lines.(35) Furthermore, Tanaka-Nakanishi et al.
found that an HTLV-1 bZIP factor impairs transcription of
Bim by disrupting FoxO3a function and acts to promote viabil-
ity of HTLV-1-infected T cells by blocking their apoptosis.(36)
In addition, our previous studies indicated that death receptor-
mediated apoptotic signals in ATL cells are strongly inhibited
at the mitochondrial level through the intrinsic apoptotic path-
way.(21) In the present study, we found that HBI-8000 is a
novel Bim activator and, as such, may be a promising agent
for treatment of ATL.
Inflammasomes are protein complexes assembled following
recognition of infection or cell damage signals, and play
important roles in apoptotic and pyroptotic cell death.(29)
The NLR proteins show a variety of functions during innate
immune response, among which NLRP3 is the most well
known. It has been shown that deregulation of NLRP3 is asso-
ciated with cancer pathogenesis, and viral infections may acti-
vate the NLRP3 inflammasome.(37–40) Previous reports have
shown the role of the NLRP3 inflammasome in antiviral
immunity towards influenza virus in vivo,(41) and a very recent
study indicated that the NLRP3 inflammasome pathway caused
quiescent CD4 T-cell death in HIV-infected hosts by caspase-
1-mediated pyroptosis.(42) Therefore, it is not surprising that
HTLV-1-infected CD4 T cells harbor an NLRP3-induced cell
death pathway. However, there is no useful method for detec-
tion of pyroptosis, such as the annexin-V/PI assay for apopto-
sis, and distinguishing apoptotic cells from pyroptosis is
difficult.(43,44)
Our purpose in the present study did not include clarifying
the mechanism of pyroptosis. Nevertheless, our microarray
analysis results strongly suggest activation of NLRP3 inflam-
masome signaling. We focused on NLRP3 and caspase-1, the
initiator and executioner, respectively, of this pathway, and
noted a clear tendency for some types of ATL cells to activate
NLRP3 and caspase-1 following treatment with HBI-8000.
Furthermore, siRNA experiments revealed that activation of
NLRP3 partly contributed to HBI-8000-induced ATL cell
death.
The importance of our results regarding NLRP3 activation
may be explained from two aspects. First, there is no known
previous report showing that antitumor drugs such as HDACi
are responsible for inflammasome-mediated cell death. Second,
our results suggest that the antiviral response by NLRP3
inflammasome is reactivated by HBI-8000 in ATL cells. This
indicates the possibility that HBI-8000 may be effective as an
antiviral agent for patients who are HTLV-1 carriers as well as
an antitumor agent for patients with ATL.
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